Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;105(1):169-183.
doi: 10.1007/s00253-020-11014-y. Epub 2020 Nov 17.

Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium

Affiliations

Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium

Fara A P Eguia et al. Appl Microbiol Biotechnol. 2021 Jan.

Abstract

The granulocyte colony-stimulating factor (G-CSF) is a hematopoietic cytokine that has important clinical applications for treating neutropenia. Nartograstim is a recombinant variant of human G-CSF. Nartograstim has been produced in Escherichia coli as inclusion bodies (IB) and presents higher stability and biological activity than the wild type of human G-CSF because of its mutations. We developed a production process of nartograstim in a 10-L bioreactor using auto-induction or chemically defined medium. After cell lysis, centrifugation, IB washing, and IB solubilization, the following three refolding methods were evaluated: diafiltration, dialysis, and direct dilution in two refolding buffers. Western blot and SDS-PAGE confirmed the identity of 18.8-kDa bands as nartograstim in both cultures. The auto-induction medium produced 1.17 g/L and chemically defined medium produced 0.95 g/L. The dilution method yielded the highest percentage of refolding (99%). After refolding, many contaminant proteins precipitated during pH adjustment to 5.2, increasing purity from 50 to 78%. After applying the supernatant to cation exchange chromatography (CEC), nartograstim recovery was low and the purity was 87%. However, when the refolding solution was applied to anion exchange chromatography followed by CEC, 91%-98% purity and 2.2% recovery were obtained. The purification process described in this work can be used to obtain nartograstim with high purity, structural integrity, and the expected biological activity. KEY POINTS: • Few papers report the final recovery of the purification process from inclusion bodies. • The process developed led to high purity and reasonable recovery compared to literature. • Nartograstim biological activity was demonstrated in mice using a neutropenia model.

Keywords: Bioreactor cultivation; G-CSF; Inclusion bodies; Purification; Recovery; Refolding.

PubMed Disclaimer

Similar articles

References

    1. Babaeipour V, Khanchezar S, Mofid MR, Abbas MPH (2015) Efficient process development of recombinant human granulocyte colony-stimulating factor (rh-GCSF) production in Escherichia coli. Iran Biomed J 19(2):102–110. https://doi.org/10.6091/ibj.1338.2015 - DOI - PubMed - PMC
    1. Babaeipour V, Mofid MR, Khanchezar S, Faraji F, Abolghasemi S (2017) Bench-scale overproduction and purification of recombinant GCSF in Escherichia coli fed-batch process. J Appl Pharm Sci 7(8):149–155. https://doi.org/10.7324/japs.2017.70821 - DOI
    1. Babior MB, Golde DW (2011) Production, distribution, and fate of neutrophils. In: Wiliams hematology chapter, vol 66, 6th edn. Mc Graw Hill Editors, New York, pp 753–784
    1. Campani G, dos Santos MP, da Silva GG, Horta ACL, Badino AC, Giordano RC, Gonçalves VM, Zangirolami TC (2016) Recombinant protein production by engineered Escherichia coli in a pressurized airlift bioreactor: a techno-economic analysis. Chem Eng Process 103:63–69. https://doi.org/10.1016/j.cep.2015.10.020 - DOI
    1. Cardoso VM, Campani G, dos Santos MP, da Silva GG, Pires MC, Gonçalves VM, Giordano RC, Sargo CR, Horta ACL, Zangirolami TC (2020) Cost analysis based on bioreactor cultivation conditions: production of a soluble recombinant protein using Escherichia coli BL21(DE3). Biotechnol Rep 26:e00441. https://doi.org/10.1016/j.btre.2020.e00441 - DOI

LinkOut - more resources